Endocrinology Flashcards
Describe the aetiology of hyperthyroidism
Grave’s disease
Nodular thyroid disease
Iodine excess
Exogenous thyroid hormone
Thyroid carcinoma
Secondary causes:
-TSH secreting pituitary tumour
-Thyroid hormone resistance
Describe the pathophysiology of Grave’s disease
Autoimmune thyroiditis caused by the production of TSH receptor stimulating antibodies
These stimulate the thyroid to produce more T3/T4
Describe the presentation of hyperthyroidism
Heat intolerance and sweating
Hyperactivity/irritability/altered mood
Palpitations
Weight loss with increased appetite
Fatigue and weakness
Fine tremor
Muscle weakness and wasting
Pretibial myxoedema
Diffuse, symmetrical goitre
Hyperreflexia
Monorrhagia
AF
Palmar erythema
Sinus tachycardia
Eyelid retraction, peri-orbital oedema, proptosis (opthalmopathy)
Give the presentation of thyrotoxic storm
Marked fever
Seizures
Vomiting
Diarrhoea
Jaundice
Death
Give the management of thyrotoxic storm
Propranolol
Corticosteroids
Carbimazole (anti-thyroid)
Give the investigations for hyperthyroidism
TFTs:
-Primary: low TSH, high T3/T4
-Secondary: high TSH, high T3/T4
TSH receptor antibodies - diagnostic for Grave’s
Radionucleide scan (Tc-99m) - diffuse widespread uptake in Grave’s
Describe the management of hyperthyroidism
Propranolol - for symptoms
Carbimazole/propylthiouracil - anti-thyroid - decrease output of T3/T4
Block and replace: high dose carbimazole + levothyroxine
Subtotal thyroidectomy: once euthyroid
Describe the management of hyperthyroidism in pregnancy
First trimester - propylthiouracil
Second and third trimester - carbimazole
Monitor fetal heartbeat (carbimazole may have effect on fetus)
Describe the aetiology of a toxic multinodular goitre
Common in older women and associated with increased iodine uptake. Strong link with amiodarone (contains iodine)
Describe thyroiditis
Autoimmune destruction of the thyroid resulting in the release of the thyroxine within
Causes a brief thyrotoxicosis, followed by a transient period of hypothyroidism
Describe De Quervain’s Thyroiditis
AKA subacute thyroiditis
4 phases:
1. Painful goitre, hyperthyroidism
2. Euthyroid
3. Hypothyroidism
4. Normal thyroid structure and function
Investigation: reduced uptake of I-131
Management: self-limiting, aspirin and NSAIDs for pain
Give two causes of pituitary space occupying lesions
Prolactinoma
Craniopharyngioma
Describe the pathophysiology of hyperprolactinaemia
Prolactin mainly controlled by tonic inhibition by hypothalamic dopamine.
Prolactin acts to induce lactation but also has inhibitory effect on GnRH secretion and the action of LH.
Describe the presentation of hyperprolactinoma
Galactorrhoea
Oligo/amenorrhoea
Reduced libido
Gynaecomastia
Subfertility
Give the investigations for prolactinoma
Serum prolactin raised
MRI head - pituitary prolactinoma
Describe the management of prolactinoma
1st line: dopamine agonist (e.g. cabergoline/bromocriptine) - DO NOT USE ROPINIROLE, this is D2 selective and therefore mostly effective in Parkinson’s
2nd line: trans-sphenoidal surgery
Describe the pathophysiology of acromegaly
Excess growth hormone, usually due to a GH secreting pituitary adenoma
Describe the presentation of acromegaly
Prominent supraorbital ridge
Large tongue
Spade-like hands and feet
Tall stature
Menstrual irregularities
Galactorrhoea
Visual field defects (due to pituitary adenoma compressing optic chiasm)
Describe the investigations for acromegaly
Insulin-like growth factor-1 (IGF-1) levels + OGTT (if GH not suppressed by glucose then diagnose acromegaly)
MRI head
Pituitary function testing
Describe the management of acromegaly
1st line: trans-sphenoidal surgery + radiotherapy
2nd line: somatostatin analogue (e.g. octreotide) +/- dopamine agonist
3rd line: GH antagonist (e.g. pegvisomant)
Why is OGTT used in the diagnosis of acromegaly?
GH is suppressed by hyperglycaemia, but would not be suppressed by hyperglycaemia in acromegaly due to the underlying pituitary adenoma
Why are dopamine agonists used in the management of acromegaly?
Dopamine inhibits GH secretion
Describe Cushing’s syndrome
Clinical state of increased free-circulating glucocorticoid
Describe the aetiology of Cushing’s syndrome
Exogenous use (most common)
ACTH-producing pituitary tumour (Cushing’s disease)
Adrenal adenoma
Describe the presentation of Cushing’s syndrome
“Moon face”
Buffalo hump
Central obesity
Proximal muscle wasting
Abdominal striae
Describe the pathophysiology of Cushing’s disease
ACTH hypersecretion from the anterior pituitary resulting in excess glucocorticoid (cortisol) production (usually due to pituitary tumour)
Describe the presentation of Cushing’s disease
Cushing’s syndrome:
-“Moon face”
-Buffalo hump
-Central obesity
-Proximal muscle wasting
-Abdominal striae
Describe the investigations for Cushing’s disease
Aim to demonstrate inappropriate cortisol secretion which is not suppressed by exogenous steroids
48 hour low-dose dexamethasone suppression test (gold standard)
24 hour urinary cortisol/ACTH levels
Adrenal/pituitary MRI
Describe the management of Cushing’s disease
TSS - MUST CONTROL CORTISOL FIRST (usually with metyrapone)
Bilateral adrenalectomy (if treatment resistant)
How does metyrapone work?
It is an 11-beta-hydroxylase inhibitor
11-beta-hydroxylase normally acts to convert 11-deoxycortisol to cortisol
Define Nelson’s syndrome
Formation of an ACTH-secreting pituitary adenoma following bilateral adrenalectomy
Describe the management of Nelson’s syndrome
TSS with prior cortisol control
Describe the pathophysiology of pituitary apoplexy
Rapid loss of pituitary function due to a bleed into the gland or an impaired vascular supply
Vascular impairment may occur as a result of a rapidly expanding tumour or a massive haemorrhage in childbirth (Sheehan’s syndrome)
Describe the presentation and management of pituitary apoplexy
Severe headache, double-vision and visual field restriction
Management: hormone replacement
Describe empty-sella syndrome
All or most of the sella is devoid of pituitary tissue
Gland is normally flattened against the fossa wall and has normal function
Usually diagnosed incidentally but may be a sign of raised ICP
Describe the aetiology of primary hyperparathyroidism
Solitary adenoma
Parathyroid hyperplasia
Carcinoma
Describe the investigations for primary hyperparathyroidism
Raised serum calcium
Low serum phosphate
Raised PTH (may be inappropriately normal)
Hand and skull XR - osteolysis in phalanges and “pepper-pot” skull
Describe the presentation of hyperparathyroidism
Classically elderly lady with an unquenchable thirst and a raised PTH
Describe the management of primary hyperparathyroidism
Total parathyroidectomy - GOLD STANDARD
Cinacalcet (calcium mimetic) v- reduced PTH secretion
Why does primary hyperparathyroidism present with unquenchable thirst?
Causes a reversible nephrogenic diabetes insipidus due to degredation of aquaporin-2 channels, leading to dehydration
Describe the pathophysiology of secondary hyperparathyroidism
Physiological compensatory hypertrophy of the parathyroid glands in response to hypocalcaemia
Describe the aetiology of secondary hyperparathyroidism
CKD and vit. D deficiency
Failing kidneys do not convert enough Vit. D to it’s active metabolite or excrete enough phosphate
This results in the formation of insoluble CaPO4 - removing calcium from the circulation
PTH therefore rises but calcium remains low
Describe the management of secondary hyperparathyroidism
Treat underlying cause, reduce dietary phosphate, Vit. D supplementation
Describe the pathophysiology of tertiary hyperparathyroidism
Autonomous increased release of PTH whilst in a hypercalcaemic state following longstanding secondary hyperparathyroidism - common in CKD
Describe the management of tertiary hyperpararthyroidism
Parathyroidectomy
Would see raised calcium and phosphate on bloods
Describe the pathophysiology of hungry bone syndrome
High pre-op PTH provides constant osteoclast stimulation
This creates a constant hypercalcaemic state due to bone demineralisation
Parathyroidectomy causes sudden drop in PTH and osteoclast activity subsequently diminishes quickly.
Bones rapidly remineralise with rapid depletion of serum calcium phosphate stores